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Abstract
Background: The tumor suppressor menin (MEN1) is mutated in the inherited disease multiple endocrine
neoplasia type I, and has several documented cellular roles, including the activation and repression of transcription
effected by several transcription factors. As an activator, MEN1 is a component of the Set1-like mixed lineage
leukemia (MLL) MLL1/MLL2 methyltransferase complex that methylates histone H3 lysine 4 (H3K4). MEN1 is
localized to the signal transducer and activator of transcription 1 (STAT1)-dependent gene, interferon regulatory
factor 1 (IRF1), and is further recruited when IRF1 transcription is triggered by interferon-g signaling.
Results: RNAi-mediated knockdown of MEN1 alters the H3K4 dimethylation and H3 acetylation profiles, and the
localization of histone deacetylase 3, at IRF1. While MEN1 knockdown does not impact the rate of transcription,
IRF1 heteronuclear transcripts become enriched in MEN1-depleted cells. The processed mRNA and translated
protein product are concomitantly reduced, and the antiviral state is attenuated. Additionally, the transcription start
site at the IRF1 promoter is disrupted in the MEN1-depleted cells. The H3K4 demethylase, lysine specific
demethylase 1, is also associated with IRF1, and its inhibition alters H3K4 methylation and disrupts the transcription
start site as well.
Conclusions: Taken together, the data indicate that MEN1 contributes to STAT1-activated gene expression in a
novel manner that includes defining the transcription start site and RNA processing.
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Background
Eukaryotic gene expression is regulated by dynamic
nuclear signaling events that occur at the chromatin
template and include post-translational modification of
the histone proteins, via methylation, phosphorylation,
acetylation and ubiquitination. Depending upon the
position of a lysine residue in the histone amino acid
sequence, histone lysine methylation is associated with
either an activated or a repressed transcriptional state
[1,2]. For example, methylation of K27 and K9 of his-
tone H3 and K20 of histone H4 correlates with tran-
scriptionally silent regions, while methylation of K4, K36
and K79 of histone H3 is associated with activated
chromatin. Lysine methylation is further elaborated by
the degree of methylation, such that mono-, di- or tri-
methylation of the same lysine residue can affect chro-
matin structure differently.
In Saccharomyces cerevisiae, a single complex contain-
ing the histone methyltransferase (HMT) Set1 is respon-
sible for the methylation of histone H3K4. In
mammalian systems, six homologs of Set1 contribute to
different Set1-like HMT complexes to accomplish this
modification [1,2]. The Set1A/Set1B complexes are most
similar to yeast Set1, and reportedly drive the majority
of the H3K4 methylation in mammalian cells [3]. The
HMT activity of the four other Set1-like complexes
derives from the mixed lineage leukemia (MLL) family
of proteins (MLL1 to MLL4), but how their gene targets
are specified is not known [4]. All the human Set1-like
complexes share a quartet of proteins, absent, small,
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binding protein 5 (RbP5), WD repeat domain 5 (WDR5)
and human dosage compensation-related protein
(hDPY-30) [5], but the interacting proteins menin
(MEN1) and pax transactivation domain-interacting pro-
tein (PTIP) are respectively specific to the MLL1/MLL2
and the MLL3/MLL4 complexes.
Menin (MEN1) is the product of the tumor suppres-
sor gene MEN1 that is mutated in the inherited syn-
drome multiple endocrine neoplasia type 1. MEN1 is
predominately localized to the nucleus, and is reported
to associate with several transcription factors to both
repress (JunD, NF-kB) and stimulate (Smad3, ERa,
VDR, PPARg) gene activation [6]. In addition, MEN1
impacts the cell cycle by promoting the expression of
cyclin-dependent inhibitors, p18
INK4c and p27
Kip1 [7,8].
Since H3K4 methylation is generally thought to posi-
tively affect transcription, and MEN1 is a component of
the Set1-like MLL1/MLL2 complexes, MEN1’sr o l ei n
transcriptional activation is thought to reflect the proper
recruitment of a co-activating H3K4 methyltransferase
to particular gene promoters [9].
There is, however, some evidence that H3K4 methyla-
tion can be repressive of transcription, in a manner that
is similar to the repressive function of the histone modi-
fication made by Set2, namely H3K36 methylation.
There, a histone deacetylase (HDAC) complex - Rpd3C
(S), that can recognize H3K36 methylation states - dea-
cetylates histones within transcribed regions to prevent
transcription from cryptic promoters located in the 3’
end of genes [10]. Similarly, the mSIN3a-HDAC1 com-
plex is recruited by H3K4 trimethylation (H3K4me3) to
repress the cyclin D gene [11,12], and two distinct
HDAC complexes, Set3-HDAC (Set3C) and Rpd3C(S),
recognize H3K4 dimethylation (H3K4me2). In the case
of Set3C, HDAC recruitment is to the 5’-end of actively
transcribed genes, and it promotes efficient transcription
[13]. In the case of Rpd3C(S), H3K4me2 is established
by cryptic transcription that begins upstream of the pro-
moter, and it is used to maintain an HDAC activity to
attenuate transcription from the normal promoter (at
GAL1)o rf r o mah i d d e np r o m o t e r( a tSUC2) [14]. Set1
activity also represses TY1 transposon transcription and
mobility in a mechanism that, again, depends upon
HDAC activity [15].
In response to external signals, the signal transducers
and activators of transcription (STAT) family of tran-
scription factors activates gene expression to promote
cellular growth, differentiation, homeostasis, inflamma-
tion and the immune response [16]. Interferon regula-
tory factor 1 (IRF1) is a primary interferon (IFN)
response gene that is highly induced by IFN-g,a n d
whose transcription is mediated by a STAT1 DNA bind-
ing element [17]. STAT1-activated gene expression of
IRF1 is rapid and transient, and requires dynamic post-
translational modification of the chromatin template,
including H3K4 methylation [18]. H3K4me3 is found at
the promoter of IRF1, and increases when this gene is
activated by IFN-g treatment. H3K4me2 is localized to
the 5’ region of this gene, in both the induced and unin-
duced states, and in cells null for STAT1 as well.
H3K4me2, therefore, is maintained via a mechanism
that does not require STAT1 triggered transcriptional
activation of IRF1. Inhibition of H3K4 HMT activity
decreases STAT1 activated gene expression and pre-
vents the inducible H3K4me3. MEN1 is associated with
the IRF1 gene locus, and is transiently recruited or sta-
bilized during IFN-g induction of STAT1 signaling.
To more fully study MEN1’sf u n c t i o na tIRF1 during
the rapid and transient gene expression invoked down-
stream of STAT1 activation, we generated a cell line
where MEN1 is depleted. The collected data point to a
mechanism for MEN1 that is more complicated than its
previously described role in regulating activated tran-
scription [19-21]. Instead, the results suggest that MEN1
and H3K4me2 function to maintain the fidelity of the
IRF1 core promoter transcriptional start site and a chro-
matin environment that efficiently promotes mRNA
processing.
Results
Characterization of MEN1 microRNA-adapted shRNA
(shRNAmir) and non-silencing shRNAmir cell lines
To determine MEN1’s mechanism at IRF1 during
STAT1-activated transcription, we generated a stable
2fTGH cell line where MEN1 is depleted using the
inducible knockdown shRNAmir vector pTRIPZ (Open
Biosystems, Huntsville AL USA, Figure 1a). A control
2fTGH cell line stably expressing a non-silencing
shRNAmir was selected as well. Quantification of wes-
tern blots of cell extracts from these two cell lines con-
sistently showed that endogenous MEN1 is reduced by
approximately 95% in the shRNAmir-MEN1 cell line
(Figure 1b). A second constitutive pGIPZ shRNAmir
vector targeting MEN1 was as effective for knockdown
and a stable cell line expressing this vector showed the
same transcriptional defects described below (data not
shown). A schematic of the IRF1 gene locus is shown in
Figure 1c.
The H3K4me2 profile at IRF1 is altered by MEN1
depletion
Previously, we profiled H3K4me2 and -me3 in response
to IFN-g induction of STAT1 signaling at the IRF1 gene,
using chromatin immunoprecipitation (ChIP) [18].
These modifications, as well as STAT1, RNA polymer-
ase II (Pol II) and MEN1, were assayed in the shRNA-
mir-MEN1 cell line and in the control cell line before
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Page 2 of 17and after treatment with IFN-g (Figure 2). STAT1 is
normally recruited to its DNA binding site (near -200
bp), as is Pol II to the transcription start site (TSS) in
MEN1-depleted cells (Figure 2a, b, c, d). MEN1, as
expected, is not localized to the promoter in response to
IFN-g in the shRNAmir-MEN1 cell line (Figure 2f), but
is recruited normally in the control cells. Surprisingly,
the profile for H3K4me3 does not appear to be altered
by MEN1 depletion in either the uninduced or induced
condition (Figure 2g, h). On the other hand, the
H3K4me2 profile is two-and-a-half times lower in the
uninduced state in the shRNAmir-MEN1 cell line, such
that the H3K4me2 level does not change when the cells
are induced with IFN-g,a si td o e si nt h ec o n t r o lc e l l
line (Figure 2i, j). The differences in the H3K4me2 ChIP
signal normally observed during induction most likely
reflect either a conversion from the dimethyl to the
trimethyl state at K4 or the recognition of the
H3K4me2 moiety by another protein, or both.
Histone H3 acetylation and HDAC3 localization are
altered in MEN1-depleted cells
The difference in H3K4me2, but not H3K4me3 in the
shRNAmir-MEN1 cell line suggested that, as in S. cerevi-
siae, two distinct chromatin environments might be
associated with these modifications [13]. In yeast,
H3K4me3 reportedly promotes high acetylation levels
and histone depletion at promoters, while H3K4me2 can
recruit HDACs to suppress acetylation. During activated
transcription, the HDAC complex Set3C deacetylates
downstream of the promoter to facilitate transcription
[13], while the Rpd3C(S) HDAC complex functions in
the transcriptionally inactive state to suppress promoter
activity [14].
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Figure 1 Characterization of MEN1-shRNAmir and non-silencing shRNAmir cell lines. (a) Graphic depiction of the pTRIPZ shRNAmir vector.
The pTRIPZ transactivator, reverse tetracycline transactivator 3 (rtTA3), binds to and activates expression from a TRE promoter in the presence of
doxycycline, for the inducible expression of an shRNAmir. (b) Western blotting of whole cell extracts from a stable 2fTGH cell line either
expressing the inducible knockdown shRNAmir vector targeting MEN1 (shMEN1) or a nonsilencing shRNAmir (NS) vector were subjected to SDS-
PAGE, blotted on nitrocellulose and a MEN1 antibody was used to develop the blots. STAT1 served as a loading control. Quantification was
performed using Image J. (c) Graphic depiction of the IRF1 gene locus (approximately 9 kb) indicating the TSS, location of the two
polyadenylation signals (inverted triangles) and locations of ChIP qPCR primers (dashes) and RACE primers (arrows) used in this study. * indicates
primers also used in qRT-PCR. ChIP: chromatin immunoprecipitation; kb: kilobases; MEN1: multiple endocrine neoplasia type 1; qPCR: quantitative
PCR; qRT-PCR: quantitative real time PCR; RACE: rapid amplification of cDNA ends; STAT1: signal transducer and activator of transcription 1; TSS:
transcription start site.
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Page 3 of 17First, to determine if there was a deacetylation defect
associated with the observed loss of H3K4me2 in the
MEN1-depleted cell line, we performed ChIP assays for
histone H3 acetylation. In order to achieve higher
resolution in the ChIP assay, cells were not fixed with
formaldehyde, and the chromatin was digested with
micrococcal nuclease rather than sheared via sonication.
In both the uninduced and induced states, significantly
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Figure 2 The H3K4 dimethylation profile at IRF1 is altered by MEN1 depletion. (a-j) Crosslinked chromatin immunoprecipitation of
shRNAmir-MEN1 (shRNA-MEN1) and shRNAmir-nonsilencing (shRNA-NS) cell lines treated with IFN-g for 30 minutes or uninduced. The indicated
antibodies were used and qPCR quantified the precipitate yield using primers spanning the IRF1 locus (see Figure 1c), reported as percent of
input. Immunoglobulin G served as the negative control. P ≤ 0.05 for 2f, i. IFN: interferon; qPCR: quantitative PCR; MEN1: multiple endocrine
neoplasia type 1.
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Page 4 of 17more (approximately three-fold) histone H3 acetylation
was immunoprecipitated from the shRNAmir-MEN1 cell
line than from the non-silencing shRNAmir control cell
line (Figure 3a, b). The H3K4me2 profiles were
essentially the same here (Figure 3c, d) as in the cross-
linked ChIP assay (Figure 2). These data suggested that
an HDAC activity might be lost or impaired in the
shRNAmir-MEN1 cell line, where H3K4me2 is low.
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Figure 3 Histone H3 acetylation and HDAC3 localization are altered in MEN1-depleted cells. (a-d) Micrococcal nuclease ChIP of shRNA-
MEN1 and shRNA-NS cell lines treated with IFN-g for 30 minutes or uninduced. The indicated antibodies were used and qPCR quantified the
precipitate yield, reported as percent of input. (e, f) Crosslinked ChIP of shRNA-MEN1 and shRNA-NS cell lines treated with IFN-g for 30 minutes
or uninduced. HDAC3 antibody was used and qPCR quantified the precipitate yield, reported as percent of input. Immunoglobulin G served as
the negative control. P ≤ 0.05 for 3a, b, c, f. ChIP: chromatin immunoprecipitation; HDAC: histone deacetylase; IFN: interferon; MEN1: multiple
endocrine neoplasia type 1; NS: nonsilencing; qPCR: quantitative PCR.
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for IFN-stimulated gene expression [22-24], and Nusin-
zon and Horvath showed that it is HDAC1 that pro-
motes IFN-ainduced transcription [23]. IFN-g induced
transcription shares the same HDAC requirement, and
HDAC1 physically interacts with STAT1, though
whether it is the HDAC activity needed is not explicitly
known [23,24]. Moreover, MEN1 has been reported to
associate with an mSin3a-HDAC1 complex for the
repression of JunD transcription [25]. Therefore, we
initially attempted to ChIP HDAC1 at the IRF1 gene
locus but were unable to detect any enrichment above
the negative control (immunoglobulin G (IgG)) levels
with nine different primer sets that spanned the region
-450 bp to +7000 bp (data not shown). A control quan-
titative PCR primer set, flanking an Sp1 binding site in
the human p21 promoter and provided by the antibody
manufacturer for use as a positive control, did show
some HDAC1 enrichment (data not shown).
Since HDAC3 is the closest mammalian homolog to
yeast Hos2, one of the histone deacetylases that contri-
butes to the Set3 complex that recognizes H3K4me2
[13,26], we also performed a ChIP assay that targeted
HDAC3. HDAC3 was ChIP’d but no difference in its
enrichment between the control and knockdown cell
lines was observed in the uninduced state. However,
when the shRNAmir-MEN1 and non-silencing control
cell lines were induced with IFN-g,t h eH D A C 3l e v e l s
increased three- to four-fold in the control cell line, but
not in the MEN1 knockdown cell line (Figure 3e, f).
Taken together, these data suggest that H3K4me2 might
provide a docking site for a complex containing
HDAC3, in order to oppose the histone H3 acetylation
that occurs at IRF1 in response to IFN-g. We attempted
to ChIP other components of a putative HDAC3 com-
plex, specifically the silencing mediator of retinoid and
thyroid receptors (SMRT) and the nuclear receptor cor-
epressor (NCoR) [13,27]. However, ChIP signals that
were significantly different from the negative control
were not observed using SMRT or NCoR antibodies, at
any position across the IRF1 locus (data not shown).
IRF1 heteronuclear RNA (hnRNA) transcripts are enriched
in the MEN1-depleted cell line
To determine if transcription of the IRF1 gene was
affected by depletion of MEN1, we performed quantita-
tive reverse transcription PCR (qRT-PCR). Using primer
pairs that are complementary to both intronic and exo-
nic IRF1 sequences, the relative abundance of IRF1 tran-
scripts in the hnRNA and total RNA pools was
determined for the shRNAmir-MEN1 and non-silencing
control cell lines, in the uninduced and induced states.
Consistently, we observed an approximately two-fold
increase in the number of IRF1 transcripts populating
the hnRNA pool in the IFN-g induced MEN1-depleted
cell line as compared to the control cell line, while the
IRF1 transcripts contributing to total RNA (exonic)
were indistinguishable between the two cell lines (Figure
4a, b). This result was rescued when the MEN1 knock-
down was reversed by overexpression of a MEN1 cDNA
(Figure 4c), and was reproduced using four additional
intronic primer pairs and one additional exonic primer
pair that span IRF1 (Additional File 1).
hnRNAs are typically short-lived, and their relative
quantities correlate with transcription rates so that qRT-
PCR using intronic primer sets can be used as a surro-
gate for the more cumbersome and less sensitive nuclear
run-off assay [28]. However, the enrichment in hnRNA
IRF1 transcripts in the MEN1-depleted cells as com-
pared to the control cells is not observed earlier in IFN-
g induction (Additional File 2), suggesting that the
increase in hnIRF1 is not simply due to an increased
rate of transcription.
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Figure 4 IRF1 hnRNA transcripts are enriched in the MEN1-
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Student’s t-test determined significance. *P ≤ 0.05. IFN: interferon;
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PCR: quantitative real time PCR.
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knockdown cells
An alternative explanation for the qRT-PCR results is
that the processed IRF1 mRNA species becomes under-
represented in the MEN1 knockdown cell line. To show
this explicitly, northern blotting was performed using
IRF1 cDNA as a probe (Figure 5a). IRF1 is alternatively
polyadenylated, and quantification of the predicted 2.1
kb IRF1 mRNA transcript and the larger 3.5 kb mRNA
transcript (Figure 1c) induced by IFN-g shows 47%
fewer of these RNA species in the MEN1 knockdown
cell line. The same result was observed in an RT-PCR
reaction designed to specifically amplify the mRNA spe-
cies (Figure 5b). The predicted PCR product of 120 bp
is 54% lower in the MEN1 knockdown cell line. Larger
RNA species that contain intronic sequences detectable
via qRT-PCR (Figure 4) were not observed via northern
blotting or RT-PCR. Since protein expression levels typi-
cally reflect mRNA expression levels, we also asked if
IRF1 expression was lower in the shRNAmir-MEN1 cells
as compared to the non-silencing control cells (Figure
5c). In three separate experiments, western blotting
showed an average 50% loss of IRF1 protein in the
induced shRNAmir-MEN1 cells, from one hour to four
hours post IFN-g induction (Figure 5d).
The decrease in IRF1 expression suggested that the
antiviral response induced by IFNs might be attenuated
in the shRNAmir-MEN1 cell line [29]. To test this idea,
the shRNAmir-MEN1 cell line was analyzed in a cyto-
pathic effect (CPE) assay as described in [30] (Figure
5e). shRNAmir-MEN1 cells were cultured with and with-
out doxycycline, treated with IFN-g IFN-aor left
untreated, then infected with dilutions of vesicular sto-
matitis virus (VSV). Western blotting showed that doxy-
cycline induced a 60% loss of MEN1 expression
(Additional File 3). In the untreated condition, there
was no difference in the CPE. However, with both IFN-g
and IFN-a, the MEN1-depleted cells were less effective
at establishing an antiviral state in this assay. The mod-
est size of the effect likely reflects the fact that IRF1
protein expression is only partially diminished in the
shRNAmir-MEN1 cell line. It is similar to the effect
observed for the STAT1 mutant, (STAT1 S727A),
where a single serine-to-alanine mutation also causes a
partial loss of its IFN-g induced transcriptional activity
[30].
The concomitant increase in IRF1 hnRNA transcripts
and decrease in IRF1 mRNA suggested that MEN1
depletion could contribute to a defect in splicing effi-
ciency. Indeed, previous research has revealed a link
between histone H3K4 methylation and splicing;
H3K4me3 is recognized by chromodomain helicase
DNA-binding protein 1 for the recruitment of spliceoso-
mal components of the U2 snRNP to enhance the rate
of the splicing reaction at IRF1 [ 3 1 ] .I nt h a ts t u d y ,a
delay in the splicing efficiency was observed early in
IRF1 induction, but it resolved quickly. When we deter-
mined the IRF1 splicing efficiency in the same way, it
appeared to proceed normally until one hour post-
induction (Figure 5f), suggesting a different mechanistic
defect in mRNA splicing occurs when MEN1 is knocked
down. Unfortunately, attempts to ChIP the splicing fac-
tor 3a complex subunits were unsuccessful. Since the C-
terminal domain (CTD) of Pol II is involved the recruit-
ment of splicing complexes [32], we assayed for altera-
tions in the phosphorylation of the CTD of Pol II using
ChIP antibodies that recognize total Pol II and serine 2
phosphorylation in the CTD, but found no significant
differences between the knockdown and control cell
lines (Additional File 4).
The IRF1 transcription start site (TSS) is disrupted in
MEN1-depleted cells
Mutation of both SET2 and the unique components of
the Rpd3C(S) complex - RCO1 and EAF3 - cause an
accumulation of aberrant transcripts starting from cryp-
tic, intragenic promoters found in the 3’-ends of genes
[33-35]. Similarly, suppression of spurious transcription
in the 5’- e n do fg e n e si saf u n c t i o np o s t u l a t e df o rt h e
yeast Set1/Set3C pathway, but such cryptic transcripts
have not been reported [13].
To determine if 5’ cryptic transcripts accumulate from
the IRF1 gene in the shRNAmir-MEN1 cell line, we per-
formed 5’ rapid amplification of cDNA ends (RACE)-
PCR assays with mRNA isolated from the MEN1-
depleted cells and control cells. In both the uninduced
and induced states, approximately 20% of the transcripts
in shRNAmir-MEN1 cells began at nucleotides that map
nine to forty-seven base pairs upstream of the canonical
TSSs, as defined by the RefSeq mRNA collection [36].
Of the IRF1 transcripts characterized from the non-
silencing shRNA control cells (Figure 6a) and wild-type
2fTGH cells, 100% started at the RefSeq TSS. Impor-
tantly, all the 5’RACE-PCR products that were purified,
cloned and sequenced showed proper splicing.
We attempted to confirm the 5’ RACE-PCR data using
primer extension analysis, but found that this approach
was not sufficiently sensitive for the detection of the
aberrant transcripts characterized via 5’ RACE-PCR.
Therefore, we developed a qRT-PCR strategy to quantify
transcripts that started upstream of the canonical TSS
for IRF1. To determine if these aberrant transcripts
were unique to the MEN1-dependent gene IRF1,w e
employed the same strategy to detect similarly aberrant
transcripts at another Pol II gene that does not depend
upon MEN1, namely GAPDH,a n da tt h eP o lIa n dP o l
III genes, RN18S1 [37] and RN7SK [38] (Additional File
5). Aberrant TSS IRF1 transcripts were detected using
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shRNAmir-NS cell lines. However, an average three-and-
a-half-fold enrichment in these aberrant TSS transcripts
was observed when MEN1 was depleted. For GAPDH,
aberrant TSS transcripts were detected as well, but not
to the same extent in both the shRNAmir-MEN1 and
shRNAmir-NS cell lines. No aberrant TSS transcripts
were detected for RN18S1 and RN7SK.
The cap analysis of gene expression (CAGE) viewer
for Homo sapiens (hg17; http://gerg01.gsc.riken.jp/cage/
hg17prmtr/) was consulted to see if any of the alterna-
tive TSSs discovered here were also found in this
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Figure 5 IRF1 mRNA becomes underrepresented in MEN1 knockdown cells. (a) Northern blot analysis of RNA collected from shRNA-MEN1
(shMEN1) and shRNA-NS (NS) cells, induced with IFN-g for 2 hours. The blot was probed with
32P-labeled IRF1 and GAPDH (loading control)
cDNA probes. Quantification was done with the Storm 840 Imager and ImageQuant TL. (b) RT-PCR of RNA collected from shRNA-MEN1 and
shRNA-NS cells, using primers designed to exon 4 (forward) and exon 5 (reverse), to specifically amplify IRF1 mRNA. b-actin primers were used as
a loading control. (c) Western blot of extracts prepared from shRNA-MEN1 and shRNA-NS cells uninduced or induced with IFN-g for indicated
times. An IRF1 antibody was used to develop the blots. GAPDH served as a loading control. (d) Graphical representation of western blots (n = 3)
as in panel C. IRF1 protein levels in the two cell lines were first normalized to GAPDH and then shRNA-MEN1 IRF1 levels were compared to
shRNA-NS IRF1 levels. Quantification was performed using Image J. Error bars are standard error. (e) Cytopathic effect of VSV in the shRNAmir-
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bars are standard error. **P ≤ 0.01, *P ≤ 0.05. IFN: interferon; MEN1: multiple endocrine neoplasia type 1; NS: nonsilencing; RT-PCR: real time PCR;
VSV: vesicular stomatitis virus.
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[39]. At the IRF1 gene promoter, a total of 86 tags were
mapped to 15 CAGE tag starting sites (CTSSs): 47% of the
tags mapped to the RefSeq TSS defined as +1; 15%
mapped to the base at -20 relative to the TSS, and 10%
mapped to the base at -11. The remaining tags represented
< 1% to 6% of the total tags. In the CAGE study, 58.6% of
tags had a pyrimidine-purine dinucleotide at positions -1,
+1, suggesting a preference for transcriptional initiation
from this sequence. All three of the major CTSSs at +1,
-11 and -20 possess the pyrimidine-purine dinucleotides at
positions -1, +1. None of the alternate TSSs we defined
have this dinucleotide sequence pattern.
We also determined the 3’-end of the IRF1 transcripts
via 3’ RACE-PCR (Figure 6b). The IRF1 mRNA is alter-
natively polyadenylated, using polyadenylation signals
approximately 2060 and 3530 bases downstream of its
5’-end [36,40]. When using a primer to exon 3, all of
the transcripts characterized from both cell lines used
the polyadenylation signal (UAUAAA), nearly identical
to the consensus signal (AAUAAA), at approximately
base 2060. Although there were some differences in the
precise cleavage site used, these differences were seen in
both the control and knockdown cell lines. The longer
IRF1 mRNA species is less prevalent, so a primer from
exon 10 was used to generate 3’ RACE-PCR products
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Figure 6 The IRF1 TSS is disrupted in MEN1-depleted cells. (a) 5’ RACE-PCR of RNA collected from shRNA-MEN1 and shRNA-NS cells, with or
without treatment with IFN-g. PCR products were generated using the 5’ RACE primer along with a reverse primer designed to the third exon of
IRF1. Arrows indicate the base position on the reverse strand of chromosome 5 to which cDNA ends mapped and the percentages reflect the
frequency that a site was observed. Asterisks mark the position of major CTSSs determined in [39] with the large asterisk indicating the RefSeq
TSS. Red indicates other minor CTSSs. 2fTGH cells, +/- IFN-g data were the same as the shRNA-NS data. (b) 3’ RACE-PCR products were
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(AAUAAA) near base 3530. All the 3’ RACE-PCR pro-
ducts that were sequenced here showed that the mRNA
was cleaved at a single site. Regardless of the primer
used, all the 3’ RACE-PCR products were of the size
predicted by the spliced mRNA. Thus, there was no evi-
dence of polyadenylated RNAs that were unspliced. We
conclude that polyadenylation occurs normally in both
the MEN1 knockdown and control cells.
Taken together, these data indicate that the IRF1 TSS
is less constrained in the cell line where MEN1 is
depleted and, more significantly, that IRF1 transcripts
are not processed as efficiently, though it is not necessa-
rily the case that these two transcriptional defects are
coupled.
Lysine specific histone demethylase 1 isoform a (LSD1) is
associated with the IRF1 gene and its inhibition also
disrupts the basal TSS
Interestingly, we observed the same loss of fidelity at the
IRF1 TSS in another experimental system where
H3K4me2 levels are modulated. Lysine specific histone
demethylase 1 isoform a (LSD1, also known as KDM1a)
is a histone H3K4 demethylase [41] that is associated
with the IRF1 promoter in both uninduced and induced
states (Figure 7a). Treatment with the LSD1-specific
inhibitor trans-2-phenylcyclopropylamine (2-PCPA)
appeared to remove LSD1 from the IRF1 promoter (Fig-
ure 7a). This result might be due to the fact that 2-
PCPA covalently modifies LSD1, and this prevents LSD1
from binding at the promoter [42]. Alternatively, the
covalent adduct might interfere with antibody recogni-
tion. Regardless, as would be predicted, LSD1 inhibition
with 2-PCPA resulted in approximately four-fold
increases in both H3K4me2 and H3K4me3 (Figure 7b,
c). LSD1 is found in complex with its cofactor, RE1-
silencing transcription factor co-repressor (CoREST),
and the histone deacetylases HDAC1 and 2 [41], and
there is an intimate functional relationship between
LSD1 and HDAC1. Both enzymes require the cofactor
CoREST and enzymatically active LSD1 is required for
efficient deacetylation by HDAC1 [42,43]. This predicted
that the IRF1 promoter would be hyperacetylated in the
uninduced 2-PCPA-treated condition. ChIP using a pan
acetyl H3 antibody confirmed this was the case; this
ChIP signal was up to 25-fold higher when cells were
treated with 2-PCPA (Figure 7d). When 5’ RACE-PCR
was performed on cells treated with 2-PCPA, 25% of the
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TSS (Figure 6c). Induction with IFN-g however,
appeared to re-establish the proper TSS.
When taken together, the data suggest that hyperace-
tylation of the IRF1 promoter, whether due to loss of
H3K4me2 as a result of MEN1 depletion, or LSD1-CoR-
EST-HDAC1 inhibition, results in fewer structural con-
straints in the chromatin template for defining the
canonical TSS.
Discussion
Histone modification and transcriptional fidelity
In this report, we demonstrate that during STAT1-trig-
gered gene activation, depletion of the Set1-like MLL1/
MLL2 complex component MEN1 is associated with
disruption of the TSS at the IRF1 core promoter, and
with diminished processing of the IRF1 hnRNA tran-
script to the mature mRNA. Depletion of MEN1 corre-
lates with decreased H3K4me2 at the IRF1 promoter,
increased H3 acetylation, and loss of HDAC3 recruit-
ment in response IFN-g induction. Moreover, IRF1 pro-
tein levels are accordingly lower when MEN1 is
knocked down, resulting in an attenuated antiviral
response in this cell line.
There are several possible explanations for the defects in
transcriptional fidelity observed here. For instance, it is
well established that the rate of elongation by Pol II
[43,44], the recruitment of splicing factors by its CTD
[44], and the core promoter itself [45] can all regulate
alternative pre-mRNA splicing. While IRF1 is not alterna-
tively spliced, and a more general deficiency in intron pro-
cessing is likely, it remains possible that these functions
are distorted in the MEN1 knockdown cell line, as experi-
ments to address some of them yielded negative results.
Perhaps more significant though is the recent but
growing evidence that chromatin structure can impact
the regulation of splicing, giving credence to the idea
that histone modifications themselves function in the
regulation of co-transcriptional RNA-processing events
[46,47]. Thus, based on the results of this study, we pro-
pose a working hypothesis in which MEN1, as part of a
Set1-like HMTase complex that targets H3K4 for
dimethylation, establishes and maintains a chromatin
environment - via HDAC3 recruitment - that promotes
transcriptional fidelity during ongoing rounds of tran-
scription. Determining the precise mechanism by which
MEN1 achieves this proper chromatin environment
requires further study and the development of new
experimental tools, effective ChIP-grade antibodies in
particular. However, these observations are somewhat
akin to those reported in yeast where the H3K4me2
modification is recognized by the Set3 complex that
deacetylates histones in 5’ transcribed regions [13]. Both
Set3 and Hos2 were shown to be required for efficient
activation of GAL1 [26], and Pol II’s interaction at this
gene was disrupted by SET3 deletion [13]. This is differ-
ent from the results reported here, in that IRF1 activa-
tion was unaffected by MEN1 depletion, and no
differences in Pol II interaction with IRF1 were
observed. Rather, we speculate that it is processing to
the mRNA that is diminished as transcription continues,
a process that is not relevant at the yeast GAL1 gene.
More recent support for our working hypothesis
comes from a report by Gunderson et al. in which
dynamic acetylation (via Gcn5) and deacetylation (via
Hos2/3) at intron-containing genes in yeast was found
to affect co-transcriptional splicing by promoting
dynamic rearrangements of the spliceosome [48]. In this
study, improperly persistent acetylation stabilized inter-
actions that are meant to be transient, slowing the
release of U2 snRNP and thereby slowing co-transcrip-
tional RNA processing. Thus, the chromatin-based co-
transcriptional defect described in this study is very
similar to the one we propose.
Histone modification and TSS fidelity
In a 2009 review of studies of H3K4 dimethylation in
yeast [49], Pinskaya and Morillon asked whether
H3K4me2-HDAC mechanisms might be conserved in
higher eukaryotes. The data reported here are the first
indication that they are. In addition, these authors pre-
sented the idea that H3K4me2 might be part of a signal-
ing pathway meant to ensure promoter fidelity, and
suggested three potential models involving a recruited
HDAC and the RNA degradation complex Nrd1/Nab3. A
similar idea was put forward by Kim and Buratowski in
considering the results of their study on the Set1-Set3C
pathway [13]. Both propose that an HDAC activity is
recruited to H3K4me2 at the promoter to remove acety-
lation on adjacent nucleosomes, in order to prevent Pol
II from initiating at uncovered TSSs. However, the pre-
dicted 5’ cryptic TSSs were not found in these yeast stu-
dies. In contrast, in our study, several alternative TSSs at
IRF1 were characterized when H3K4me2 levels were
experimentally modulated. Thus, this is the first direct
evidence of an H3K4me2-HDAC mechanism in main-
taining eukaryotic TSS fidelity by Pol II. In future studies,
the hypothesis that H3K4me2 recruits a particular
HDAC complex in the uninduced state will be addressed.
We suspect that once transcription is induced, TSS fide-
lity comes to depend less on how the chromatin architec-
ture was established in the uninduced state. This might
explain why it was difficult to detect RNA transcripts
from alternative TSSs, even after IFN-g induction.
A novel role for MEN1 in activated gene expression
The results of this study suggest a different and more
complicated function for MEN1 in STAT1-activated
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during the inducible expression of other genes. As
examples, three studies of nuclear receptor (NR)-
mediated transcriptional activation have described a co-
activating role for MEN1. MEN1 directly interacts with
ERa and PPARg, and acts as a co-activator during their
ligand activated transcription [19,20]. MEN1 can also
co-activate VDR mediated transcription [21]. In these
cases, loss of MEN1 leads to decreased expression of
NR target gene mRNAs (as measured by qRT-PCR), in
response to NR ligand addition, and lower H3K4me3 at
these genes’ promoters. Thus, MEN1’s role in transcrip-
tional activation is understood to simply reflect the
proper recruitment of a co-activating methyltransferase
to gene promoters for the methylation of histone H3 at
K4 [9].
We do not observe any change in the enrichment of
H3K4me3 at the IRF1 promoter when MEN1 is
depleted. Nor do we observe any loss in total IRF1 RNA
levels. These dissimilar observations might reflect differ-
ences in the kinetics of gene activation by NRs versus
STATs. But, it is also possible that STAT1-activated
gene expression requires regulation from the chromatin
e n v i r o n m e n tt h a ti sd i s t i n c tf r o mt h a tn e e d e dd u r i n g
NR-activated gene expression, and that MEN1 contri-
butes by establishing and maintaining the necessary
levels of H3K4me2 at STAT1-dependent promoters.
The same explanation is likely true when comparing our
results to those reported at the constitutive HOXA9
locus [50]. There, MEN1 excision correlates with a two-
fold loss of H3K4me3. Going forward, it will be impor-
tant to tease apart if or how the Set1-like MLL1/MLL2
complexes, of which MEN1 is a component, specifically
generate the sharp peak of H3K4 trimethylated histones
versus the broader peak of dimethylated histones at the
5’ end of genes, since these two methyl marks appear to
foster the opposing activities of acetylation and deacety-
lation. And it will be interesting to determine how the
different functions of the Set1-like MLL1/MLL2 com-
plexes are specified at different genes. In other words,
when is the straightforward co-activating function,
requiring H3K4me3, delivered as opposed to the more
complicated H3K4me2-HDAC function?
HDAC activity is required for IFN-g induced gene
expression
Prior to our study, the use of HDAC inhibitors had
firmly established deacetylation as a requirement in anti-
viral gene expression induced by IFNs [51]. Type I IFNs
require at least one class I deacetylase, HDAC1, and it is
possible that another HDAC is also involved [22,24].
The type II IFN pathway also requires deacetylation.
The HDAC inhibitors trichostatin A, sodium butyrate
and suberoylanilide hydroxamic acid prevent IFN-g
inducible Janus kinase 1 activation, STAT1 phosphoryla-
tion, nuclear translocation and the activation of a
STAT1-responsive luciferase reporter gene [23]. RNAi
mediated knockdown and overexpression of HDAC1,
H D A C 2a n dH D A C 3m o d u l a t e st r a n s c r i p t i o no ft h i s
same reporter construct. The HDAC inhibitors also
lower IRF1 expression induced by IFN-g.
We found evidence that HDAC3 is recruited to IRF1
in response to IFN-g and that when this fails to occur,
the associated histones become hyperacetylated. Our
interpretation of these data is that the inappropriate
‘openness’ of the chromatin template contributes to the
loss of definition at the TSS, and to the inefficient pro-
cessing of IRF1 pre-mRNA to the mature mRNA. IRF1
protein is, therefore, not expressed to sufficient levels,
and the antiviral state is diminished. So, while HDAC
inhibition revealed that acetylation and/or deacetylation
events affect many steps in the type II IFN pathway
[23], we propose that at least one of these processes
involves HDAC3 recruitment to establish and maintain
a conducive chromatin environment during IFN-g
induced gene expression.
Alternative TSSs at the IRF1 promoter
CAGE has shown that mammalian TSSs are not only
defined by a single well-defined base pair [39]. Rather,
mammalian promoters can also initiate transcription
from multiple sites spread across a region. The assort-
ment of TSSs in the human genome characterized by
CAGE was classified according to shape. The four shape
classes are: single dominant peak; broad; bi- or multi-
modal; and broad with a dominant peak.
The IRF1 gene does not have a typical TATA box,
although there is an AT rich sequence starting at -38
relative to the TSS, and it does appear to have a
CCAAT box at -99 and a GC box at -162. Its TSS is
d e f i n e db yas i n g l ed o m i n a n tp e a kt h a tm a p st ot h e
nucleotide at 131,854,364 on the reverse strand of chro-
mosome 5. This is the same base that defines the TSS
in our study and the RefSeq mRNA. The other minor
CTSSs (14) map to base +4 and -66 bases from this site.
While most of the minor CTSSs are from singleton
CAGE tags, the CTSS at -11 and -20 were found in dif-
ferent RNA libraries and, in fact, are the major CTSSs
in a RNA library produced from a large intestine malig-
nancy. The alternative TSSs described here are proximal
to these TSSs; thus, it is interesting to consider the pos-
sibility that loss of TSS fidelity away from the single
peak might be generally associated with malignancy, and
that epigenetic dysregulation, involving H3K4me2 at
promoters, could contribute to this process.
The fact that we could detect aberrant TSS transcripts
using a qRT-PCR strategy (Additional File 5) for
GAPDH is also supported by the CAGE analysis; like
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its canonical TSS [39]. Importantly, however, these aber-
rant TSS GAPDH transcripts were not enriched in the
MEN1-depleted cells.
Conclusions
Based on the results of this study, we hypothesize a
novel role for MEN1 in which it, as part of the Set1-
like MLL1/MLL2 complex, regulates the dimethyla-
tion of H3K4. H3K4me2 is then recognized for the
proper recruitment of HDAC3, which in turn pre-
vents the hyperacetylation of the chromatin template
at IRF1, when its transcription is triggered by IFN-g.
Without HDAC3’s opposing activity, the chromatin
template becomes too ‘open’ and the information it
provides for the regulation of gene expression is
compromised, resulting in a poorly defined TSS and
inefficient RNA processing. Thus, the post-transla-
tional modification of histones modulates not only
the transcriptional processes of initiation, elongation
and termination, but co-transcriptional processes as
well.
Methods
Antibodies
H3K4me3 (Abcam ab8580), RNA Pol II Ser2 (Abcam
ab5095), LSD1/KDM1 (Abcam ab17721), HDAC3
(Abcam ab7030-50), NCoR (Abcam ab24552) and
GAPDH (Abcam ab9485) were from Abcam, Cambridge
MA USA. H3K4me2 (Millipore 07-030), Pan H3 CT
(Millipore 07-690), Acetyl Histone H3 (Millipore 06-
599), HDAC1 (Millipore 17-608) and SMRT (Millipore
17-10057) were from Millipore, Billerica MA USA. RNA
Pol II (Santa Cruz sc-899), STAT1 (Santa Cruz sc-345X)
and IRF1 (Santa Cruz sc-497) were from Santa Cruz
Biotechnology, Santa Cruz CA USA. Menin (Bethyl
A300-105A) was from Bethyl Laboratories, Montgomery
TX USA. IgG and anti-rabbit or anti-mouse HRP were
from Jackson Immunoresearch, West Grove PA USA.
Splicing factor 3a antibodies were a gift from Angela
Krämer (University of Geneva).
Cell lines and chemical inhibitors
2fTGH cells were cultured in HyClone DMEM/high glu-
cose medium (HyClone, Rockford IL USA) supplemen-
ted with 10% cosmic calf serum and 10% antibiotic/
antimycotic (Fisher Scientific, Pittsburgh PA USA). IFN-
g treatment in all cases involved adding IFN-g (R&D
Systems, Minneapolis MN USA 5 ng/mL) to the med-
ium for 30 minutes, replacing with fresh medium and
harvesting cells at the indicated times. Cells were treated
with 100 μM 2-PCPA for 24 hours (Sigma-Aldrich, St.
Louis MO USA) prior to experimentation.
Transfection of shRNAmir and expression vectors
An inducible pTRIPZ shRNAmir vector targeting menin
(MEN1) mRNA (RHS4696-99702478), as well as a non-
silencing shRNA vector (RHS4743) were purchased
from Open Biosystems, Huntsville AL USA. A second
pGIPZ shRNAmir vector targeting menin (RHS4430-
98819991, Open Biosystems) also was characterized.
Transfection of 2fTGH cells with each was carried out
using Arrest-In reagent according to the manufacturer’s
protocol (Open Biosystems). Puromycin (3 μg/mL) was
used to select for stable cell lines. Cells were treated
with 2 μg/mL of doxycycline (Fisher Scientific, Pitts-
burgh PA USA) 24 hours prior to induction to activate
the pTRIPZ vector and characterized based on menin
protein expression by western blotting. C-terminally
FLAG-tagged MEN1 was PCR cloned using the AscI
and MluI sites of pCMV6-entry (OriGene PS100001,
Origene, Rockville MD USA) and the MEN1 cDNA as
template (Open Biosystems, IHS1380-97652628).
ChIP
Crosslinked ChIP was performed as described in [52].
Briefly, 1 × 10
7 cells were fixed in 1% formaldehyde for
10 minutes followed by the addition of 0.125 M glycine.
Cells were lysed using a douncer and the fixed chroma-
tin was sheared by sonication. For micrococcal nuclease
ChIP, 1 × 10
7 cells were collected and lysed using a
dounce homogenizer. Cells were digested with 100
units/mL of micrococcal nuclease (Worthington, Lake-
wood NJ USA). Sheared or digested chromatin was then
incubated overnight with various antibodies. Pan H3
and IgG were included in all ChIPs as positive and
negative controls. Immunoprecipitation was carried out
with protein A or G agarose and salmon sperm DNA
beads (Millipore). After washing, the chromatin was
eluted from the beads and the crosslinks were reversed
by heating at 65°C overnight. DNA was treated with
RNase A and Proteinase K (5 Prime, Gaithersburg MD
USA), purified via phenol and chloroform extraction,
precipitated with ethanol overnight and resuspended in
tris-ethylenediaminetetraacetic acid buffer. Samples were
analyzed by qRT-PCR (Applied Biosystems Carlsbad CA
U S A )u s i n gg e n es p e c i f i cp rimers designed to run the
length of the IRF1 gene. Primer sequences can be pro-
vided upon request. PCR efficiency was determined for
all primer pairs before their use. Data are expressed as
percentage of input and all experiments were performed
in duplicate, if not triplicate. One replicate is shown in
Figures 2, 3 and 7. To ensure the statistical significance
of differences reported in the ChIP assays, standard
errors were calculated for the multiplicates and, if
necessary, a Student’s t-test confirmed significance, P ≤
0.05 [53].
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Total RNA was collected using Isol-RNA lysis reagent (5
Prime). RNA was DNaseI (Life Technologies, Grand
Island NY USA) treated and extracted with phenol and
chloroform. RNA (2 μg) was converted to cDNA using
the High Capacity RNA-to-cDNA kit (Applied Biosys-
tems). cDNA was then subjected to Q-PCR (SYBR
Green, 7500 FAST Real Time PCR System, Applied Bio-
systems) using gene specific primers to the intronic or
exonic regions of the IRF1 gene. In all cases, an RT
negative control confirmed no genomic DNA contami-
nation. Primer sequences can be provided upon request.
PCR efficiency was determined for all primer pairs
before their use by using genomic DNA as template. To
ensure the statistical significance of differences reported
in the qRT-PCR assays, standard errors were calculated
for the multiplicates and a Student’st - t e s tc o n f i r m e d
significance, P ≤ 0.05 [53]. To quantify aberrant TSS
transcripts (n = 2), primers that flank the canonical
RefSeq TSS for the IRF1 and GAPDH (Pol II genes)
genes, and the RN7SK (Pol III gene) gene were used, as
were primers that quantify total mRNA or snRNA tran-
scripts for each of these genes. IRF1 aberrant TSS (for-
ward; 5’-CCGCTAAGTGTTTGGATTGC, reverse; 5’-
CTCGGGCGCACGTCTT), IRF1 total (forward: 5’-AAA
GGAGCCAGATCCCAAGAC; reverse: 5’- GGTGGA
AGCATCCGGTACAC), GAPDH aberrant TSS (for-
ward: 5’- GCGCCCCCGGTTTCTATA; reverse: 5’-
GATGCGGCTGACTGTCGAA), GAPDH total (for-
ward: 5’-GACAACTTTGGTATCGTGG; reverse; 5’-
GGTGGCAGTGATGGCATGG), RN7SK aberrant TSS
(forward: 5’-TGTAAAGTTGAGACTTCCTTCAGGTT;
reverse: 5’- AACCCTGGCGATCAATGG), RN7SK total
(forward: 5’-TCTTCGGTCAAGGGTATACGAGTAG;
reverse: 5’- TACAAATGGACCTTGAGAGCTTGT). Q-
PCR primers that could quantify aberrant TSS tran-
scripts for the 45S rRNA that is processed to 18S rRNA
(RN18S1; a Pol I gene) could not be designed using Pri-
mer Express (Applied Biosystems) and so standard RT-
PCR was performed, except that a second 25 cycle
amplification was performed using a 10% aliquot of the
first PCR reaction as template. This primer pair ampli-
fies a product of the correct size when genomic DNA is
the template. RN18S1 aberrant TSS (forward: 5’-
CGGGTTATTGCTGACACGC; reverse: 5’- CCGCG
CGCATCCGGAGGCCCAAC), RN18S1 total (forward:
5’- GTGCCAAGCAGCCGCGGTAA; reverse: 5’-GGGC
ATCACAGACCTG).
RT-PCR
RT was as described above. PCR was performed (20
cycles) using primers designed to IRF1 exon 4 (forward:
5’-CTGCCAGATATCGAGGAGGTGAAA-3’)a n de x o n
5 (reverse: 5’-TCTTGGCCTTGCTCTTAGCATCTC-3’).
Western blotting
Cells were collected after various treatments and whole
cell extract, prepared as described in [54], was subjected
to SDS-PAGE (30 μg) and transferred to a nitrocellulose
membrane. Immunodetection was performed using the
indicated antibodies. A horseradish peroxidase anti-spe-
cies secondary antibody (1:10,000) was then applied and
immunoreactive proteins were visualized using chemilu-
minescence reagent (Fisher Scientific, Pittsburgh PA
USA). Histone acid extraction was carried out as
described previously [55]. Bands were quantified with
ImageJ software.
Northern blotting
Total RNA was extracted from shRNAmir-MEN1 and
shRNAmir-NS cells using Isol-RNA lysis reagent (5
Prime). Equal amounts of RNA (20 μg) were electro-
phoretically separated on a 1.5% agarose-formaldehyde
gel. The RNA was transferred to a nylon membrane by
capillary action and fixed by baking. The northern blots
were probed with [
32P]-labeled IRF1 (Open Biosystems
IHS1380-97433442) and GAPDH (Open Biosystems
IHS1380-97434647) cDNAs prepared using the DECA-
prime II kit (Ambion Life Technologies, Grand Island
NY USA). Phosphor screens were exposed to probed
blots, and the band intensity was quantified with Storm
840 Imager and ImageQuant TL software (GE Health-
care, Piscataway NJ USA).
CPE assay
CPE assays (n = 2) were performed as described in [30].
The titered VSV Indiana strain was a generous gift from
Gail Wertz (University of Virginia). shRNAmir-MEN1
cells were grown in HyClone DMEM/high glucose med-
ium supplemented with 10% tetracycline-screened fetal
bovine serum and 10% antibiotic/antimycotic (Fisher).
Cells were cultured with or without 2 μg/mL of doxycy-
cline (Fisher Scientific). Approximately 8000 cells per
well were plated in 96-well dishes and allowed to grow
overnight. Cells were untreated, treated with IFN-g
(R&D Systems, 10 ng/mL) or IFN-a (R&D Systems,
1000 U/mL) for 12 hours and then infected with various
dilutions of VSV for approximately 15 hours. The viral
medium was removed, cells were fixed with 5% formal-
dehyde and stained with 0.05% crystal violet. shRNAmir-
NS cells did not phenocopy 2fTGH cells in this assay,
perhaps due to an off-target effect that becomes relevant
in this biological response assay. Therefore shRNAmir-
MEN1 (-) doxycycline cells were used as the control.
5’ and 3’ RACE-PCR
RNA was isolated from 2fTGH cell lines under various
conditions. RACE-PCR was performed using the Gene
Racer Kit (Invitrogen). PCR products were generated
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well as IRF1 specific primers designed to exon 3 (for-
ward: 5’-CCCAGCTCCGGAACAAACAGGCATCC-3’)
for 3’R A C E ,o re x o n3( r e v e r s e :5 ’-GGATGCCT
GTTTGTTCCGGAGCTGGGC-3’)f o r5 ’ RACE or exon
10 (forward: 5’-CAGTCACAGACAGAACAGTCAG-
CAGCCC-3’)f o r3 ’ RACE. Products were gel purified
a n dc l o n e di n t ot h eT O P Ov e c t o r( p C R 4 - T O P O ) .
TOP10 competent cells were transformed and plasmid
DNA was isolated from multiple clones using the Qiagen
Spin Miniprep Kit (Qiagen, Valencia CA USA). DNA was
then sequenced with M13F and M13R primers provided
in the TOPO cloning kit. Sixteen or seventeen clones
were sequenced for each of the different conditions. A
Fisher’s exact test determined significance.
Additional material
Additional File 1: IRF1 hnRNA transcripts are enriched in the MEN1-
depleted cell line. (a-e) qRT-PCR to quantitate IRF1 total and pre-mRNA
expression in shRNA-MEN1 and shRNA-NS cell lines that were uninduced
(un) or treated with IFN-g. IRF1 expression was normalized to b-actin and
presented as fold change relative to the uninduced, shRNA-NS condition.
Numbers are the base pair location of the primers used on the IRF1
gene; see Figure 1c. Error bars are standard error (n = 4). **P ≤ 0.01, *P ≤
0.05.
Additional File 2: Increased rate of transcription does not account
for elevated hnRNA pool in the shRNAmir-MEN1 cell line. (a-b) qRT-
PCR to quantitate IRF1 pre-mRNA and total RNA expression in shRNA-
MEN1 and shRNA-NS cell lines that were uninduced or treated with IFN-g
and collected at indicated time points. IRF1 expression was normalized to
b-actin and presented as fold change relative to the uninduced, non-
silencing shRNAmir condition. Error bars are standard error (n = 4). **P ≤
0.01.
Additional File 3: CPE assay MEN1 protein levels. (a) MEN1 western
blot of whole cell extracts prepared from shRNA-MEN1 cells treated with
doxycycline for 24 hours or not. GAPDH served as the loading control.
Additional File 4: Phosphoserine 2 Polymerase II levels are not
altered in the MEN1-depleted cell line. (a, b) Chromatin
immunoprecipitation of shRNA-MEN1 and shRNA-NS cell lines treated
with IFN-g for 90 minutes or uninduced using the antibody specific for
the phosphoserine 2 form of Pol II.
Additional File 5: Aberrant TSS transcripts at Pol I, Pol II and Pol II
genes. (a) qRT-PCR to quantitate transcripts initiated from a TSS
upstream of the canonical TSS for IRF1, GAPDH and RN7SK (a Pol III gene)
in shRNA-MEN1 and shRNA-NS cell lines. IRF1, GAPDH and RN7SK mRNA
transcripts and aberrant TSS transcripts were normalized to b-actin; the
aberrant TSS transcripts were calculated as a fraction of total mRNA, and
presented as fold enrichment relative to the non-silencing shRNAmir
condition. Error bars are standard error (n = 2). A student’s one-tailed t-
test determined significance. *P ≤ 0.05. (b) Effective qPCR primers could
not be designed at the TSS of the 45S rRNA that is processed to 18S
rRNA (RN18S1, a Pol I gene) and so endpoint PCR was used to attempt
to detect aberrant TSS transcripts. 25 cycles of PCR did not generate an
amplicon, nor did a second round of 25 cycles using an aliquot (10%) of
the first reaction as template (arrow), but when genomic DNA was used
a template an amplicon of the correct size was produced (positive
control). This experiment was done for two biological replicate cDNA
preparations, though only one is shown. 18S ORF primers detect the
RN18S1 rRNA. RT+ indicates reverse transcriptase was included in the
cDNA reaction while RT- indicates it was omitted.
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